Weekly Journal Scan: improved renal outcomes by semaglutide in patients with chronic kidney disease and type 2 diabetes in FLOW trial

作者
Daniela Pedicino,Massimo Volpe
出处
期刊:European Heart Journal [Oxford University Press]
卷期号:45 (38): 3910-3911 被引量:3
标识
DOI:10.1093/eurheartj/ehae429
摘要

Comment on the article ‘Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes’ which was published in the New England Journal of Medicine, https://doi.org/10.1056/NEJMoa2403347. The FLOW (Evaluate Renal Function with Semaglutide Once Weekly) study is a company-funded, randomized, double-blind, placebo-controlled, event-driven, superiority trial, assessing the efficacy and safety of the glucagon-like peptide-1 (GLP-1) receptor agonist, semaglutide, on renal outcomes in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD).1 Subjects were randomly assigned 1:1 to receive either subcutaneously once-weekly semaglutide (1.0 mg) or a visually identical placebo, added to standard-of-care therapy.1 A total of 3433 patients were enrolled at 387 sites across 28 countries. Eligibility criteria included a diagnosis of T2D with glycated haemoglobin level ≤ 10%, high-risk CKD, and a stable dose of renin–angiotensin system (RAS) inhibitors. Kidney disease was defined as an estimated glomerular filtration rate (eGFR) of 25–75 mL/min/1.73 m2, with a urinary albumin-to-creatinine ratio of >300 and <5000 if the eGFR was ≥50 mL/min/1.73 m2 or a urinary albumin-to-creatinine ratio of >100 and <5000 for eGFR ranging between 25 and 50 mL/min/1.73 m2. The primary outcome was major kidney disease events, a composite of onset of kidney failure (initiation of long-term dialysis, kidney transplantation, or a reduction in the eGFR to <15 mL/min/1.73 m2 sustained for ≥28 days), a sustained (for ≥28 days) 50% or greater reduction in eGFR from baseline, or death from kidney-related or cardiovascular causes. Confirmatory secondary outcomes included eGFR slope (i.e. the annual rate of change in eGFR from randomization to the end of the trial); major cardiovascular events (a composite of non-fatal myocardial infarction, non-fatal stroke, or death from cardiovascular causes); and death from any cause. The mean age of participants was 67 years (30% women, 66% White), with a mean glycated haemoglobin level of 8%, a mean body mass index (BMI) of 32, and a duration of T2D longer than 15 years in more than half. The mean eGFR was 47 mL/min/1.73 m2 (11% of patients had eGFR < 30 mL/min/1.73 m2) and the median urinary albumin-to-creatinine ratio was 568. Up to 23% of patients had a previous cardiovascular event (myocardial infarction or stroke). Only 16% of patients received sodium-glucose co-transporter (SGLT)-2 inhibitors, and more than 90% were treated with RAS inhibitors. Two-thirds of participants were estimated to be at very high risk for kidney disease progression, kidney failure, cardiovascular events, or death.2 Based on a pre-specified interim analysis, the trial was stopped prematurely on the grounds of efficacy. At completion, the median participant follow-up was 3.4 years, with vital status known for 99% of participants and an average of 89% adherence to study treatment during the study period. Primary outcome events occurred less frequently in the semaglutide group [331 events vs. 410; hazard ratio (HR), 0.76; 95% confidence interval (CI), 0.66–0.88; P = .0003; number needed to treat, 59 per year of treatment]. Lower risk with semaglutide was also observed for a composite of the kidney-specific components of the primary outcome (HR, 0.79; 95% CI, 0.66–0.94), as well as for death from cardiovascular causes (HR, 0.71; 95% CI, 0.56–0.89). Results were consistent across pre-specified subgroups, including eGFR and glycated haemoglobin range, BMI, medications, race, and previous cardiovascular events. The mean annual slope of the eGFR was less steep in the semaglutide group (between-group difference, 1.16 mL/min/1.73 m2; 95% CI, 0.86–1.47; P < .001). The risk of major cardiovascular events was 18% lower in the semaglutide group than in the placebo group (212 vs. 254 events; HR, 0.82; 95% CI, 0.68–0.98; P = .029), and the risk of death from any cause was 20% lower (227 vs. 279 events; HR, 0.80; 95% CI, 0.67–0.95; P = .01). The mean change in body weight and glycated haemoglobin level from baseline to Week 104 was greater in the semaglutide group than in the placebo group, by 4.1 kg and 0.8%, respectively. Serious adverse events were reported in fewer participants in the semaglutide group than in the placebo group (50% vs. 54%), mostly driven by less serious infections and less serious cardiovascular events. Gastrointestinal symptoms represented the main cause of semaglutide permanent discontinuation. Chronic kidney disease affects more than 800 million people worldwide, especially in low- and middle-income countries, and is particularly prevalent among individuals with T2D.3 Due to an increased risk of kidney failure, cardiovascular events and death, CKD is still associated with significantly high morbidity and mortality, with the consequence of a huge social and economic burden, and the critical need for more effective prevention and treatment strategies. This is particularly true in subjects with T2D and obesity, in whom mechanisms underlying the development and progression of CKD, such as glomerular hyperfiltration, low-grade inflammation, oxidative stress, increased tubular sodium reabsorption, and activation of the RAS, are amplified.4 Renin–angiotensin system inhibitors and SGLT-2 inhibitors showed beneficial effects on kidney function and cardiovascular events and currently represent established treatments for CKD and T2D.5–8 In spite of the positive effects of these therapies, patients with CKD and T2D remain at high risk of progression of renal failure, major cardiovascular events, and death. Recent evidence suggests a potential protective effect of GLP-1 receptor agonists in this setting. Most of the data supporting this hypothesis, however, have been based on the analysis of secondary or post hoc renal endpoints, in studies performed in patients with and without CKD, where renal outcomes were derived from exploratory analyses.9 A recent study examined the effect of once-weekly semaglutide 2.4 mg on kidney outcomes in the SELECT trial population, showing a clinical benefit (22% reduction in the pre-specified main kidney endpoint) in high-risk individuals with overweight/obesity and without diabetes.10 The FLOW trial is the first randomized trial specifically designed to investigate the effect of semaglutide on renal outcomes in the CKD population.1 This is one of the major strengths of the study, along with the large sample size, the relatively long follow-up, and the high rate of treatment adherence with only modest treatment discontinuation. Although the subjects enrolled were not selected based on body weight or BMI, the study population largely consisted of an overweight/obese cohort (mean BMI 32), although the beneficial effects of semaglutide appeared to be independent of the limited weight loss or the modest effect on the glycaemic profile. These considerations underscore the potential contributory role of other mechanisms of action, which could also at least partly justify the observed reduction in major cardiovascular events and mortality and thus deserve further investigation. Although the benefits of semaglutide were obtained in a very well-treated population, receiving stable maximal doses of RAS inhibitors, the number of patients taking SGLT2 inhibitors was modest and the semaglutide effect size was highly statistically uncertain. Thus, this trial cannot clarify whether semaglutide adds an appreciable benefit in patients who are already on SGLT2 inhibitors. Similarly, the non-steroidal antagonist of mineralocorticoids, finerenone, which is reported to exert sizeable renal protection in CKD/T2D patients, was not included in the therapy of the patients studied.11,12 Besides these relevant limitations, the large prevalence of White individuals compared with other ethnicities strongly affects the generalizability of the results, particularly for the Black population in which CKD and T2D are frequent. Finally, the study was not designed and powered to assess the cardiovascular effects of semaglutide; thus, it cannot be considered conclusive in this regard, despite a very encouraging and statistically significant effect on major cardiovascular events. In conclusion, the ground-breaking results of the FLOW trial, showing a clear reduction in the risk of kidney disease-related events, support the use of semaglutide in patients with CKD and T2D. Further studies are needed to define the effects obtained in association or in alternative to other effective drug classes, such as SGLT2 inhibitors and finerenone, to assess the potential cardiovascular benefits and to extend the representativity of all ethnic groups and non-obese subjects. D.P. received speaker’s fees from Daiichi Sankyo, outside the submitted work. M.V. reports personal fees for speaker bureau and/or consulting in Advisory Boards from Astra Zeneca, Bayer, GSK, Menarini Int, Novartis Pharma, Novo Nordisk, Pfizer, Sanofi Pasteur, and Servier. M.V. is supported by a research grant from Italian Ministry of Health (‘Ricerca corrente’).

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
漫不经心完成签到,获得积分10
刚刚
朴素小馒头完成签到,获得积分10
刚刚
凉花落酒完成签到,获得积分10
1秒前
存存完成签到 ,获得积分10
1秒前
田様的应助被段晓倩采纳,获得10
1秒前
Martin的应助被木谦采纳,获得20
1秒前
李健的应助被纯真从寒采纳,获得10
1秒前
懒人完成签到,获得积分10
2秒前
2秒前
枫华西数发布了新的文献求助10
2秒前
MINGMING完成签到,获得积分10
2秒前
焦糖咸鱼发布了新的文献求助10
3秒前
筑梦完成签到,获得积分10
3秒前
现代菠萝完成签到,获得积分10
3秒前
twosix完成签到,获得积分10
3秒前
sunny发布了新的文献求助10
3秒前
MoChin完成签到,获得积分10
3秒前
夏夏子发布了新的文献求助10
3秒前
郭娅楠发布了新的文献求助10
4秒前
我想静静完成签到,获得积分10
4秒前
阿欢完成签到,获得积分10
4秒前
Lee_d发布了新的文献求助10
4秒前
懒惰依秋发布了新的文献求助10
4秒前
慕青的应助被miss张采纳,获得10
4秒前
YC发布了新的文献求助20
4秒前
樊庭完成签到,获得积分10
5秒前
苹果南烟发布了新的文献求助10
6秒前
天行马完成签到,获得积分10
6秒前
6秒前
水波不兴完成签到 ,获得积分10
6秒前
vegdog完成签到,获得积分10
6秒前
陆焉识完成签到 ,获得积分10
7秒前
123高人发布了新的文献求助10
7秒前
动如脱兔完成签到,获得积分10
7秒前
7秒前
太叔千愁完成签到,获得积分10
7秒前
7秒前
zhangliyingfly完成签到,获得积分10
8秒前
zoe完成签到 ,获得积分10
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology)求助 1000
Encyclopedia of Modern Artificial Intelligence 1000
John McDowells Bildungstheorie 800
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Synthesis, Application and Future Perspectives of Smart Nano-materials - Part 1 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8152442
求助须知:如何正确求助?哪些是违规求助? 9549069
关于积分的说明 21690841
捐赠科研通 7740658
什么是DOI,文献DOI怎么找? 3425157
关于科研通互助平台的介绍 2550382
邀请新用户注册赠送积分活动 2468710